JW Cayman Therapeutics : VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE SHARES OF THE COMPANY IN THE HONG KONG STOCK CONNECT LIST UNDER THE SHENZHEN-HONG KONG STOCK CONNECT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

JW (Cayman) Therapeutics Co. Ltd ᖹ׼̶ፕ€කਟϞࠢʮ̡*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2126)

VOLUNTARY ANNOUNCEMENT

INCLUSION OF THE SHARES OF THE COMPANY IN THE HONG KONG STOCK CONNECT LIST UNDER THE SHENZHEN-HONG KONG STOCK CONNECT

This announcement is made by JW (Cayman) Therapeutics Co. Ltd (the "Company", together with its subsidiaries, collectively the "Group") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the "Board") is pleased to announce that the Company has been included in the Hong Kong Stock Connect list under the Shenzhen-Hong Kong Stock Connect, with effect on March 15, 2021, pursuant to the Announcement on Adjustment of the list of the Hong Kong Stock Connect under Shenzhen-Hong Kong Stock Connect issued by the Shenzhen Stock Exchange on March 15, 2021.

The Board is of the view that the Company's inclusion in the Hong Kong Stock Connect list under the Shenzhen-Hong Kong Stock Connect demonstrates the recognition of the Company's business, liquidity of stock and future prospect of the Company by the investors in the capital markets, which is expected to expand the shareholder base, diversify the shareholder structure and increase the trading liquidity of the Company. It is believed that the inclusion will facilitate to realize the investment value of the Company and enhance the Company's reputation in the capital market.

ABOUT THE COMPANY

Co-founded by Juno Therapeutics (now a BMS company) and WuXi AppTec, the Company is a leading clinical and pre-clinical stage cell therapy company in China with an integrated platform focusing on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors.

The Company's vision is to develop innovative cell therapies for the China market to transform the treatment of cancer for Chinese patients. The Company has built a comprehensive and differentiated cell therapy pipeline covering both hematological cancers and solid tumors. Its lead product, relmacabtagene autoleucel, an anti-CD19 CAR-T therapy for relapsed or refractory B-cell lymphoma, is expected to be the first CAR-T therapy to be approved as a Category 1 biologics product in China.

By order of the Board

JW (Cayman) Therapeutics Co. Ltd ᖹ׼̶ፕ€කਟϞࠢʮ̡*

Yiping James Li

Chairman

Shanghai, People's Republic of China, March 15, 2021

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yiping James Li as Chairman and executive Director, Mr. Hans Edgar Bishop, Dr. Krishnan Viswanadhan, Ms. Xing Gao, Dr.

Ann Li Lee, Mr. Jinyin Wang, Dr. Cheng Liu as non-executive Directors, and Mr. Yanling Cao, Mr. Chi Shing Li, Mr. Yiu Leung Andy Cheung, Mr. Kin Cheong Kelvin Ho as independent non-executive Directors.

* For identification purpose only